Altimmune Ownership
| ALT Stock | USD 4.29 0.09 2.14% |
Shares in Circulation | First Issued 2005-06-30 | Previous Quarter 71.3 M | Current Value 75.5 M | Avarage Shares Outstanding 13.8 M | Quarterly Volatility 23 M |
Altimmune | Build AI portfolio with Altimmune Stock |
Altimmune Stock Ownership Analysis
About 48.0% of the company shares are held by institutions such as insurance companies. The book value of Altimmune was presently reported as 1.83. The company recorded a loss per share of 1.26. Altimmune last dividend was issued on the 20th of January 2017. The entity had 1:30 split on the 14th of September 2018. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. For more info on Altimmune please contact Vipin Garg at 240 654 1450 or go to https://altimmune.com.Besides selling stocks to institutional investors, Altimmune also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Altimmune's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Altimmune's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Altimmune Quarterly Liabilities And Stockholders Equity |
|
Altimmune Insider Trades History
Less than 1% of Altimmune are currently held by insiders. Unlike Altimmune's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Altimmune's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Altimmune's insider trades
Altimmune Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Altimmune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Altimmune backward and forwards among themselves. Altimmune's institutional investor refers to the entity that pools money to purchase Altimmune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bellevue Group Ag | 2025-03-31 | 1.1 M | Schroder Investment Management Group | 2025-03-31 | 961.9 K | Ubs Group Ag | 2025-03-31 | 788.2 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 657.2 K | Northern Trust Corp | 2025-03-31 | 636.7 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 492.5 K | Goldman Sachs Group Inc | 2025-03-31 | 390.3 K | Rfg Advisory Group, Llc | 2025-03-31 | 324.4 K | Beirne Wealth Consulting Services, Llc | 2025-03-31 | 294.5 K | Blackrock Inc | 2025-03-31 | 6.1 M | Vanguard Group Inc | 2025-03-31 | 4.4 M |
Altimmune Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Altimmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Altimmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Altimmune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Altimmune Outstanding Bonds
Altimmune issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Altimmune uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Altimmune bonds can be classified according to their maturity, which is the date when Altimmune has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Altice France 8125 Corp BondUS02156LAA98 | View | |
| ALTICE FRANCE S Corp BondUS02156LAE11 | View | |
| Altice France 55 Corp BondUS02156LAC54 | View | |
| US02156LAH42 Corp BondUS02156LAH42 | View | |
| US02156LAF85 Corp BondUS02156LAF85 | View | |
| Altice Europe 5 Corp BondUS02154CAF05 | View | |
| US02154CAH60 Corp BondUS02154CAH60 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.